Clinical Trial DRUG KCP-330-008
- A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician’s Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation
- Principal Investigator
- Olga Frankfurt
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG KCP-330-008
- The purpose of this study is to evaluate the effects of KPT-330 in treatment of relapsed/refractory acute myleloid leukemia(AML).
- Relapsed/refractory AML can have limited treatment options. The medical and scientific communities are always looking at promising treatments. The study drug, KPT-330, is an investigational drug. It has not been approved by the U.S. Food & Drug Administration. KPT-330 works by trapping certain proteins in the cell and cause the cancer cells to die or stop growing. KPT-330 has been tested to establish a safe dose. This study will look at what effects, good and/or bad, has on AML and the participants by comparing it to treatment by current standard drugs.
Some of the eligibility criteria include:
- Participants must be at least 60 years of age or older.
- Participants must have relapsed(cancer came back)/refractory(cancer does not respond to treatment)acute myeloid leukemia (AML).
- Participants have not undergone and are not eligible for stem cell transplantation.
- Description of Treatment
- This is a randomized (like the flip of a coin) study. Participants will be assigned to one of two groups, 2/3 of participants will be put into group 1. Group 1 will take KPT-330 orally (by mouth) twice a week. Group 2 will receive one of 3 current standard treatments for AML. The study doctor will decide which one a participant in group 2 will receive. Participants will remain on the study until their disease worsens or the study doctor feels it is in their best interest to stop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Olga Frankfurt
- CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (Ind #73969, Nsc #732517) as Primary Therapy Followed by Transplantation for Adults = 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
- An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
- Phase III, Multicenter, Randomized, Trial Of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years Of Age with Untreated High Risk (Secondary) AML
- A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
- An Open Label, Multi-Center Imatinib Roll-Over Protocol for Patients who Have Completed a Previous Novartis sponsored Imatinib Study and are Judged by the Investigator to Benefit from Continued Imatinib Treatment
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia
last updated: 20-Oct-14 12:56 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.